Freely Filtered 057: NephMadness 2023 TMA
Freely Filtered, a NephJC Podcast
Is Avocopan an Oral C5 Inhibitor?
For factor B and C3, I am particularly excited about them for C3G because they are targeting more proximal in the complement pathway. And then the Avocopan, which we're seeing approved for Incavascularitis, it's an oral C5 inhibitor. Do folks think about that as like a future maintenance therapy that's easier than coming in for IV echolizumab? Or I know that's super off label and no one should be doing that, but right.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
